Jiaqi Hao

Ms. Jiaqi Hao


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2024 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
XGXiuya Guan
Xiuya Guan
YHYuanlong Hu
Yuanlong Hu
JHJiaqi Hao
Jiaqi Hao
MLMengkai Lu
Mengkai Lu
ZZZhiyuan Zhang
Zhiyuan Zhang
CLChao Li
Chao Li

5 July 2025 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
JZJiaming Zhang
Jiaming Zhang
MLMengkai Lu
Mengkai Lu
XGXiuya Guan
Xiuya Guan
JHJiaqi Hao
Jiaqi Hao
YLyunlun li
yunlun li
CLChao Li
Chao Li

Verified
Journal Article
Open access
PDF file
MZMuxin Zhang
Muxin Zhang
ZWZicheng Wang
Zicheng Wang
MLMengkai Lu
Mengkai Lu
JHJiaqi Hao
Jiaqi Hao
YLyunlun li
yunlun li
Atherosclerosis remains the leading cause of cardiovascular mortality worldwide. Vascular smooth muscle cells (VSMCs) were long regarded as passive structural elements of the arterial wall, but they are now recognized as highly plastic cells capable of transdifferentiating into macrophage-like cells (MLCs). This conversion promotes plaque inflammation, matrix degradation, and necrotic core expansion, yet the mechanisms that control it remain poorly defined. This review synthesizes current understanding of the multilayered regulatory networks that govern VSMC-to-MLC transdifferentiation. These networks couple upstream signaling through MAPK, Notch, TGF-β, and PI3K/AKT to master transcription factors such as KLF4, IRF7, and ZEB2. They further extend to epigenetic mechanisms encompassing DNA methylation, histone modifications, non-coding RNAs, and metabolic reprogramming involving cholesterol efflux and lipophagy. We then assess therapeutic strategies that prevent or reverse this conversion, including miRNA replacement, kinase inhibition, LXR activation and autophagy induction. We further highlight unresolved questions on MLC heterogeneity, reversibility, and targeted delivery, outlining priorities for translating these insights into clinical benefit.